华东医药
(000963)
| 流通市值：576.75亿 | | | 总市值：577.88亿 |
| 流通股本：17.51亿 | | | 总股本：17.54亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,410,809,128.72 | 40,623,782,520.43 | 30,394,530,509.51 | 20,385,344,288.81 |
| 营业收入 | 10,410,809,128.72 | 40,623,782,520.43 | 30,394,530,509.51 | 20,385,344,288.81 |
| 二、营业总成本 | 9,331,357,509.92 | 37,081,915,122.91 | 27,539,505,233.9 | 18,443,622,876.24 |
| 营业成本 | 7,076,397,110.06 | 27,461,731,573.59 | 20,711,433,505.92 | 13,917,418,061.11 |
| 税金及附加 | 56,334,556.14 | 232,590,269.39 | 155,063,860.73 | 106,685,622.91 |
| 销售费用 | 1,574,261,928.29 | 6,645,411,414.21 | 4,662,350,509.65 | 3,083,786,005.03 |
| 管理费用 | 335,169,160.39 | 1,420,188,961.59 | 1,105,836,120.39 | 721,477,862.62 |
| 研发费用 | 281,639,751.64 | 1,270,803,119.96 | 840,788,063.58 | 558,407,142.27 |
| 财务费用 | 7,555,003.4 | 51,189,784.17 | 64,033,173.63 | 55,848,182.3 |
| 其中:利息费用 | 23,050,131.41 | 119,514,554.96 | 84,321,926.54 | 55,401,149.67 |
| 其中:利息收入 | 24,409,865.24 | 94,045,345.71 | 61,683,137.57 | 33,022,555.87 |
| 加:公允价值变动收益 | -25,364.49 | -13,756,372.8 | -6,616,639.87 | -5,100,698.38 |
| 加:投资收益 | -47,163,448.93 | -219,713,034.52 | -168,842,873.72 | -136,885,042.56 |
| 资产处置收益 | 1,521,275.31 | 4,319,797.54 | 3,587,637.81 | 3,519,820.08 |
| 资产减值损失(新) | - | -6,519,844.03 | -3,175,583.57 | -3,175,583.57 |
| 信用减值损失(新) | - | -25,763,586.64 | -42,022,538 | -36,432,398.31 |
| 其他收益 | 38,311,729.18 | 172,492,861.66 | 70,617,560.34 | 34,813,373.7 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,072,095,809.87 | 3,452,927,218.73 | 2,708,572,838.6 | 1,798,460,883.53 |
| 加:营业外收入 | 1,295,600.39 | 50,548,825.6 | 3,536,981.13 | 2,972,826.61 |
| 减:营业外支出 | 5,202,610.91 | 37,490,279.21 | 24,000,149 | 16,298,554.8 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,068,188,799.35 | 3,465,985,765.12 | 2,688,109,670.73 | 1,785,135,155.34 |
| 减:所得税费用 | 207,943,278.46 | 619,588,815.15 | 494,560,848.37 | 345,279,440.91 |
| 六、净利润 | 860,245,520.89 | 2,846,396,949.97 | 2,193,548,822.36 | 1,439,855,714.43 |
| 持续经营净利润 | 860,245,520.89 | 2,846,396,949.97 | 2,193,548,822.36 | 1,439,855,714.43 |
| 归属于母公司股东的净利润 | 862,411,560.96 | 2,838,860,542.8 | 2,189,046,844.62 | 1,433,824,629.56 |
| 少数股东损益 | -2,166,040.07 | 7,536,407.17 | 4,501,977.74 | 6,031,084.87 |
| (一)基本每股收益 | 0.49 | 1.62 | 1.25 | 0.82 |
| (二)稀释每股收益 | 0.49 | 1.62 | 1.25 | 0.82 |
| 八、其他综合收益 | 40,589,535.1 | 50,506,468.03 | -3,888,970.61 | -8,889,448.01 |
| 归属于母公司股东的其他综合收益 | 40,589,535.1 | 50,506,468.03 | -3,888,970.61 | -8,889,448.01 |
| 九、综合收益总额 | 900,835,055.99 | 2,896,903,418 | 2,189,659,851.75 | 1,430,966,266.42 |
| 归属于母公司股东的综合收益总额 | 903,001,096.06 | 2,889,367,010.83 | 2,185,157,874.01 | 1,424,935,181.55 |
| 归属于少数股东的综合收益总额 | -2,166,040.07 | 7,536,407.17 | 4,501,977.74 | 6,031,084.87 |
| 公告日期 | 2024-04-26 | 2024-04-18 | 2023-10-25 | 2023-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |